Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
balstilimab + ivermectin
- Development stage
- Unknown
- Lead developer
- Agenus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Balstilimab + ivermectin is an investigational combination therapy being studied for the treatment of metastatic triple-negative breast cancer (TNBC). Balstilimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. Ivermectin, traditionally used as an antiparasitic agent, has demonstrated immunomodulatory and potential anticancer properties by increasing tumor infiltration of CD4+ and CD8+ T-cells and reducing myeloid-derived suppressor cells in preclinical models. The rationale for this combination is that ivermectin may "prime" tumors—turning immunologically "cold" tumors into "hot" ones—thereby enhancing the efficacy of immune checkpoint blockade with balstilimab. Clinical trials are ongoing to evaluate safety, optimal dosing, and preliminary efficacy in patients with metastatic TNBC[1][2][4][5][6][7].
- Other names
- balstilimab and ivermectinivermectin and balstilimab
02
Targets
GluCl (Glutamate-gated chloride channel)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on balstilimab + ivermectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on balstilimab + ivermectin.